Medical office trades on income as $6.7B rebound takes hold

Medical office buildings generated $6.7 billion of investment volume in the first half of 2026, up 21 percent from a year earlier, while transaction count fell 15 percent and the average trade climbed to $20 million, according to Cushman & Wakefield's MOB Capital Markets Mid-Year 2026 Update. The shift points to a market consolidating around institutional-scale assets rather than broad small-building churn, with cap-rate compression following as competition for those fewer, larger buildings firmed pricing.

The same $6.7 billion first-half figure appeared in this publication's prior coverage of medical outpatient sales. Medical outpatient sales jumped 21 percent as the portfolio premium widened, and Cushman & Wakefield's report frames the rebound around income: steady rent growth, tight supply, and high occupancy remain the draw, with income returns above 5.5 percent for seven consecutive quarters and appreciation returns turning positive.

Rents rose 2 percent year over year, and the report notes that inflation is beginning to outpace rent growth. If rents rise 2 percent while the broader price level runs hotter, the real income stream shrinks in purchasing-power terms. That pushes the investment case toward a bond proxy with a maintenance-heavy asset attached.

Lenders have arrived with the same income-first posture, as origination volume jumped 88 percent year over year, banks supplied nearly three-quarters of medical office debt over the past five years, and fixed debt costs sit 80 basis points below their 2023 peak. The report also notes greater willingness to accept fixed-rate risk and higher loan-to-value ratios, the language of a lending market comfortable with a slow, predictable asset class.

Elevated construction costs keep new supply constrained, which supports occupancy but keeps the replacement-cost floor high. The pace of monetary easing is uncertain as inflationary pressures persist, and fixed debt costs that look attractive today could stay put or move against new buyers. Cushman & Wakefield still calls medical office "one of the most compelling investment opportunities within commercial real estate," and that conclusion is defensible if income remains the objective.

The portfolio premium this publication tracked in its last medical outpatient story shows up in the rising average deal size, and that is a legitimate rebound. But the market has re-priced medical office as a cash-flow asset, and the buyers winning the competition will be the ones who underwrite rent growth as a cushion instead of a growth engine. Watch two numbers: the 2 percent rent-growth figure and the 80-basis-point gap between today's fixed debt costs and the 2023 peak. If the first holds and the second narrows, the first half of 2026 will look like the slow part of the year.